Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.

ABSTRACT:

Aim

To evaluate the changes in renal endpoints in type 2 diabetes patients treated with dapagliflozin versus other glucose-lowering medications in routine clinical practice.

Materials and methods

DARWIN-T2D was a retrospective study conducted at 46 outpatient diabetes clinics in Italy. An automated software collected data on 17 285 patients who received dapagliflozin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, or gliclazide, 6751 of whom had a follow-up visit. We analysed changes in albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR).

Results

Patients who received dapagliflozin (n = 473) were younger, more obese, and had a poorer glucose control than those who received a comparator (n = 2973). After ~6 months

SUBMITTER: Fadini GP 

PROVIDER: S-EPMC6585815 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature